ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer
View abstract on PubMed
Summary
This summary is machine-generated.Gastric cancer exhibits widespread RNA misediting, linked to ADAR1/2 dysregulation and poor prognosis. Targeting ADAR enzymes offers potential new therapies for this deadly malignancy.
Area Of Science
- Molecular Biology
- Epigenetics
- Oncology
Background
- Gastric cancer (GC) is a leading cause of cancer mortality globally.
- Adenosine-to-inosine RNA editing, mediated by ADAR enzymes, is an epigenetic mechanism with emerging roles in cancer.
- The specific involvement of RNA editing and ADARs in GC development and progression is largely unknown.
Purpose Of The Study
- To investigate the RNA editing landscape in gastric cancer.
- To determine the role of ADAR enzymes (ADAR1 and ADAR2) in GC pathogenesis.
- To explore the clinical and functional implications of RNA editing alterations in GC.
Main Methods
- Utilized next-generation sequencing transcriptomics to analyze GC samples.
- Examined ADAR1 and ADAR2 gene expression and copy number variations.
- Performed in vitro and in vivo functional assays to assess the impact of ADARs on GC.
- Analyzed clinical data from independent cohorts to correlate ADAR dysregulation with patient prognosis.
Main Results
- Gastric cancers predominantly show a distinct RNA misediting phenotype compared to normal tissues.
- ADAR1 and ADAR2 genes are frequently dysregulated in GC due to genomic copy number alterations.
- ADAR1/2 imbalance in GC patients correlates with significantly poorer prognoses.
- ADAR1 and ADAR2 exhibit reciprocal roles in GC pathogenesis, with ADAR1 being oncogenic and ADAR2 tumor-suppressive.
- ADAR2-mediated editing of PODXL at codon 241 induces a loss-of-function, reducing tumorigenicity.
Conclusions
- RNA editing plays a significant role in GC development and progression, potentially overlooked by DNA-focused analyses.
- ADAR enzyme dysregulation is a key feature of GC.
- Targeting ADAR1 for enzymatic inhibition or restoring ADAR2 activity presents novel therapeutic strategies for gastric cancer.